S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20
S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20
S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20
S&P 500   4,594.62
DOW   34,899.34
QQQ   391.20
NASDAQ:RGNX

REGENXBIO Stock Forecast, Price & News

$30.96
-2.25 (-6.78%)
(As of 11/26/2021 12:00 AM ET)
Add
Compare
Today's Range
$30.25
$32.80
50-Day Range
$30.90
$45.04
52-Week Range
$27.02
$50.26
Volume
263,400 shs
Average Volume
406,773 shs
Market Capitalization
$1.32 billion
P/E Ratio
N/A
Dividend Yield
N/A
Beta
0.97
30 days | 90 days | 365 days | Advanced Chart
Receive RGNX News and Ratings via Email

Sign-up to receive the latest news and ratings for REGENXBIO and its competitors with MarketBeat's FREE daily newsletter.


REGENXBIO logo

About REGENXBIO

REGENXBIO, Inc. is a clinical-stage biotechnology company, which engages in the development, commercialization, and licensing of recombinant adeno-associated virus gene therapy. Its product candidates include NAV Technology Platform, which consists of exclusive rights to novel adeno-associated viral vectors; and therapeutic programs such as RGX-314, RGX-202, RGX-121, RGX-111, RGX-181, and RGX-381. The company was founded by Kenneth T. Mills and James M. Wilson on July 16, 2008 and is headquartered in Rockville, MD.

Headlines

REGENXBIO (NASDAQ:RGNX) Shares Gap Down to $37.79
November 15, 2021 |  americanbankingnews.com
REGENXBIO Inc. (NASDAQ:RGNX) CEO Sells $60,000.00 in Stock
November 10, 2021 |  americanbankingnews.com
See More Headlines

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:RGNX
Fax
N/A
Employees
306
Year Founded
N/A

Sales & Book Value

Annual Sales
$154.57 million
Book Value
$10.79 per share

Profitability

Net Income
$-111.25 million
Net Margins
-228.08%
Pretax Margin
-221.91%

Debt

Price-To-Earnings

Miscellaneous

Free Float
37,466,000
Market Cap
$1.32 billion
Optionable
Optionable

Company Calendar

Last Earnings
11/02/2021
Today
11/29/2021
Fiscal Year End
12/31/2021
Next Earnings (Estimated)
3/07/2022

MarketRank

Overall MarketRank

2.49 out of 5 stars

Medical Sector

125th out of 1,391 stocks

Biological Products, Except Diagnostic Industry

16th out of 201 stocks

Analyst Opinion: 4.4Community Rank: 4.7Dividend Strength: 0.0Insider Behavior: 3.3Valuation: 0.0 5 -4 -3 -2 -1 -












REGENXBIO (NASDAQ:RGNX) Frequently Asked Questions

Is REGENXBIO a buy right now?

8 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for REGENXBIO in the last year. There are currently 2 hold ratings, 5 buy ratings and 1 strong buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" REGENXBIO stock.
View analyst ratings for REGENXBIO
or view top-rated stocks.

How has REGENXBIO's stock been impacted by Coronavirus (COVID-19)?

REGENXBIO's stock was trading at $32.89 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, RGNX stock has decreased by 5.9% and is now trading at $30.96.
View which stocks have been most impacted by COVID-19
.

When is REGENXBIO's next earnings date?

REGENXBIO is scheduled to release its next quarterly earnings announcement on Monday, March 7th 2022.
View our earnings forecast for REGENXBIO
.

How were REGENXBIO's earnings last quarter?

REGENXBIO Inc. (NASDAQ:RGNX) posted its quarterly earnings results on Tuesday, November, 2nd. The biotechnology company reported ($1.37) EPS for the quarter, missing the Zacks' consensus estimate of ($0.87) by $0.50. REGENXBIO had a negative trailing twelve-month return on equity of 44.70% and a negative net margin of 228.08%. During the same quarter in the previous year, the firm posted $0.23 EPS.
View REGENXBIO's earnings history
.

What price target have analysts set for RGNX?

8 equities research analysts have issued 12 month price objectives for REGENXBIO's stock. Their forecasts range from $17.00 to $90.00. On average, they expect REGENXBIO's stock price to reach $58.25 in the next year. This suggests a possible upside of 88.1% from the stock's current price.
View analysts' price targets for REGENXBIO
or view top-rated stocks among Wall Street analysts.

Who are REGENXBIO's key executives?

REGENXBIO's management team includes the following people:
  • Kenneth T. Mills, President, Chief Executive Officer & Director
  • Curran M. Simpson, SVP, Chief Operations & Technology Officer
  • Vit Vasista, Chief Financial Officer & Senior Vice President
  • Olivier Danos, Chief Scientific Officer & Senior Vice President
  • Stephen Pakola, Chief Medical Officer & Senior Vice President

What is Ken Mills' approval rating as REGENXBIO's CEO?

3 employees have rated REGENXBIO CEO Ken Mills on Glassdoor.com. Ken Mills has an approval rating of 68% among REGENXBIO's employees.

What other stocks do shareholders of REGENXBIO own?

Based on aggregate information from My MarketBeat watchlists, some companies that other REGENXBIO investors own include AbbVie (ABBV), Micron Technology (MU), NVIDIA (NVDA), Voyager Therapeutics (VYGR), Amarin (AMRN), CRISPR Therapeutics (CRSP), Pfizer (PFE), QUALCOMM (QCOM), Gilead Sciences (GILD) and Square (SQ).

What is REGENXBIO's stock symbol?

REGENXBIO trades on the NASDAQ under the ticker symbol "RGNX."

Who are REGENXBIO's major shareholders?

REGENXBIO's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (14.87%), RTW Investments LP (4.31%), Dimensional Fund Advisors LP (1.56%), Geode Capital Management LLC (1.56%), First Manhattan Co. (1.33%) and Goldman Sachs Group Inc. (0.88%). Company insiders that own REGENXBIO stock include Allan M Fox, Curran Simpson, Donald J Hayden Jr, Kenneth T Mills, Kenneth T Mills, Patrick J Christmas, Vittal Vasista and WR Stephens, Iii 2012 Trust.
View institutional ownership trends for REGENXBIO
.

Which major investors are selling REGENXBIO stock?

RGNX stock was sold by a variety of institutional investors in the last quarter, including Dimensional Fund Advisors LP, Carmignac Gestion, Invesco Ltd., Millennium Management LLC, Morgan Stanley, WS Management Lllp, South Dakota Investment Council, and Russell Investments Group Ltd.. Company insiders that have sold REGENXBIO company stock in the last year include Allan M Fox, Curran Simpson, Kenneth T Mills, Patrick J Christmas, Vittal Vasista, and WR Stephens, Iii 2012 Trust.
View insider buying and selling activity for REGENXBIO
or view top insider-selling stocks.

Which major investors are buying REGENXBIO stock?

RGNX stock was acquired by a variety of institutional investors in the last quarter, including Jane Street Group LLC, First Manhattan Co., BlackRock Inc., Assenagon Asset Management S.A., Two Sigma Investments LP, Voloridge Investment Management LLC, RTW Investments LP, and Connor Clark & Lunn Investment Management Ltd..
View insider buying and selling activity for REGENXBIO
or or view top insider-buying stocks.

How do I buy shares of REGENXBIO?

Shares of RGNX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is REGENXBIO's stock price today?

One share of RGNX stock can currently be purchased for approximately $30.96.

How much money does REGENXBIO make?

REGENXBIO has a market capitalization of $1.32 billion and generates $154.57 million in revenue each year. The biotechnology company earns $-111.25 million in net income (profit) each year or ($5.17) on an earnings per share basis.

How many employees does REGENXBIO have?

REGENXBIO employs 306 workers across the globe.

What is REGENXBIO's official website?

The official website for REGENXBIO is www.regenxbio.com.

Where are REGENXBIO's headquarters?

How can I contact REGENXBIO?

REGENXBIO's mailing address is 9600 BLACKWELL ROAD SUITE 210, ROCKVILLE MD, 20850. The biotechnology company can be reached via phone at (240) 552-8181 or via email at [email protected].


This page was last updated on 11/29/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.